- Home
- HUN vs GH Comparison
HUN vs GH Comparison
Compare HUN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUN
- GH
- Stock Information
- Founded
- HUN 1970
- GH 2011
- Country
- HUN United States
- GH United States
- Employees
- HUN N/A
- GH N/A
- Industry
- HUN Major Chemicals
- GH Medical Specialities
- Sector
- HUN Industrials
- GH Health Care
- Exchange
- HUN Nasdaq
- GH Nasdaq
- Market Cap
- HUN 4.2B
- GH 4.3B
- IPO Year
- HUN 2005
- GH 2018
- Fundamental
- Price
- HUN $16.77
- GH $37.46
- Analyst Decision
- HUN Hold
- GH Strong Buy
- Analyst Count
- HUN 9
- GH 14
- Target Price
- HUN $23.33
- GH $39.93
- AVG Volume (30 Days)
- HUN 2.3M
- GH 1.8M
- Earning Date
- HUN 02-19-2025
- GH 02-20-2025
- Dividend Yield
- HUN 5.95%
- GH N/A
- EPS Growth
- HUN N/A
- GH N/A
- EPS
- HUN N/A
- GH N/A
- Revenue
- HUN $5,987,000,000.00
- GH $692,256,000.00
- Revenue This Year
- HUN N/A
- GH $32.21
- Revenue Next Year
- HUN $4.99
- GH $16.90
- P/E Ratio
- HUN N/A
- GH N/A
- Revenue Growth
- HUN N/A
- GH 29.20
- 52 Week Low
- HUN $15.95
- GH $15.81
- 52 Week High
- HUN $27.01
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- HUN 32.41
- GH 66.67
- Support Level
- HUN $15.95
- GH $34.80
- Resistance Level
- HUN $18.15
- GH $37.46
- Average True Range (ATR)
- HUN 0.42
- GH 1.78
- MACD
- HUN -0.04
- GH 0.51
- Stochastic Oscillator
- HUN 34.53
- GH 80.49
About HUN Huntsman Corporation
Huntsman Corp is a us-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. It derives most of its revenue from the Polyurethanes segment which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.